Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Celcuity Inc. - Common Stock
(NQ:
CELC
)
102.09
-0.52 (-0.51%)
Streaming Delayed Price
Updated: 10:40 AM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Celcuity Inc. - Common Stock
< Previous
1
2
Next >
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
October 06, 2025
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:LPTX),(NASDAQ:IOBT),(NASDAQ:CELC),(NYSE:MAIA) EQNX::TICKER_END
Via
FinancialNewsMedia
Peraso (NASDAQ: PRSO) Powers Military, Nex-Gen Broadband Surge – Mag 7 Undercard VAPE CELC, CRVO – More Stocks Inside
July 28, 2025
Via
AB Newswire
Topics
Supply Chain
Celcuity Inc. Announces $50 Million Private Placement
October 18, 2023
Via
ACCESSWIRE
Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors
September 14, 2022
Via
ACCESSWIRE
Celcuity Set to Join Russell 2000 and 3000 Indexes
June 20, 2023
Via
ACCESSWIRE
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
May 24, 2023
Via
ACCESSWIRE
Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates
May 15, 2023
Via
ACCESSWIRE
Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress
May 12, 2023
Via
ACCESSWIRE
Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call
May 08, 2023
Via
ACCESSWIRE
Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress
May 08, 2023
Via
ACCESSWIRE
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
April 18, 2023
Via
ACCESSWIRE
Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
Via
ACCESSWIRE
Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 23, 2023
Via
ACCESSWIRE
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call
March 16, 2023
Via
ACCESSWIRE
Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
March 15, 2023
Via
ACCESSWIRE
Celcuity to Participate in Cowen's 43rd Annual Health Care Conference
March 01, 2023
Via
ACCESSWIRE
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium
February 16, 2023
Via
ACCESSWIRE
Celcuity Closes $100 Million Private Placement
December 12, 2022
Via
ACCESSWIRE
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium
December 09, 2022
Via
ACCESSWIRE
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer
December 07, 2022
Via
ACCESSWIRE
Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium
November 22, 2022
Via
ACCESSWIRE
Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference
November 10, 2022
Via
ACCESSWIRE
Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022
Via
ACCESSWIRE
Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call
November 03, 2022
Via
ACCESSWIRE
Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022
Via
ACCESSWIRE
Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call
August 04, 2022
Via
ACCESSWIRE
Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference
August 03, 2022
Via
ACCESSWIRE
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
July 18, 2022
MINNEAPOLIS, MN / ACCESSWIRE / July 18, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today...
From
Celcuity Inc.
Via
AccessWire
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
May 26, 2022
MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...
From
Celcuity Inc.
Via
AccessWire
Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates
May 16, 2022
- Entered into $100 Million Private Placement Agreement - Finalized pivotal Phase 3 trial design for gedatolisib - Received FDA Fast Track designation for gedatolisib in HR+/HER2- advanced breast...
From
Celcuity Inc.
Via
AccessWire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
